The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure

Conference Correspondent  - ESMO 2018

Ovarian carcinoma has the highest mortality rate among gynecologic malignancies, due in part to the primary drug resistance and multidrug resistance that represent major clinical obstacles to treatment.1 Apatinib is a small-molecule tyrosine kinase inhibitor independently developed in China that mainly functions by competitively blocking the binding of VEGF with VEGFR-2 and preventing the autophosphorylation of VEGFR-2. Antitumor effects are thereby elicited by preventing VEGF-mediated endothelial cell proliferation and migration, and reducing tumor angiogenesis. In this prospective, open-label, single-arm clinical trial, Sun and colleagues evaluated the efficacy and safety of apatinib mesylate as treatment after failure of second-line chemotherapy in patients with advanced epithelial ovarian cancer.2

Of 17 evaluable patients who received oral apatinib for 3 treatment cycles (each cycle included 500 mg or 250 mg apatinib once daily for 28 days), 6 (35.3%) and 2 (11.8%) patients achieved partial response and stable disease, respectively. The objective response rate (ORR) and disease control rate (DCR) were 35.3% and 47.1%, respectively. Efficacy signals were not significantly different between groups receiving initial dosages of 500 mg (ORR, 30%; DCR, 30%) and 250 mg (ORR, 42.8%; DCR, 71.4%). The median progression-free survival was 2.2 months (95% confidence interval [CI], 1.0-8.9 months) and the median overall survival was 6.3 months (95% CI, 1.5-12.8 months). The most common adverse events reported were hypertension (70.6%), hand-foot syndrome (52.9%), and oral mucosa damage (35.3%).

The results of this study suggest that oral apatinib treatment is efficacious and well-tolerated in patients with advanced epithelial ovarian cancer who have failed second-line chemotherapy.

References

  1. Norouzi-Barough L, et al. J Cell Physiol. 2018;233(6):4546-4562.
  2. Sun S, et al. ESMO 2018. Abstract 974P.
Related Items
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
A Phase 1b and Randomized Phase 2 Trial of Pazopanib with or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Maintenance Olaparib Following Platinum-Based Chemotherapy in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA1/2 Mutation: Results from the Phase 3 SOLO1 Trial
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 2 Trial of Combination Nivolumab and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
Association of PD-L1 Expression with Clinical Response to Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Meta-Analysis of PARP-Inhibitor–Associated Gastrointestinal and Hepatic Toxicities
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
Conference Correspondent  published on October 20, 2018 in ESMO 2018
A Phase 2 Study of Durvalumab, a PD-L1 Inhibitor, and Olaparib in Recurrent Ovarian Cancer
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Last modified: October 22, 2018